- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: ASP4058 is an orally active, next-generation sphingosine 1-phosphate (S1P) receptor agonist that shows selectivity for S1P1 and S1P5 over other S1P receptors in vitro . Most likely used as the hydrochloride salt (PubChem CID 16755142). Compare this with the non-selective S1P agonist fingolimod, which was the first oral drug to be approved for relapsing forms of MS.
Studies in animal models suggests that ASP4058 may also be beneficial in ameliorating the chronic arterial wall inflammation observed as underlying intracranial aneurysm (IA) .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|S1P receptor agonists are known to regulate lymphocyte trafficking and thereby produce an immunomodulatory effect. Therapeutic potential in MS is suggested by results from expermiments in a rodent model of MS .|
|Relapsing-remitting multiple sclerosis||
||ASP4058 ameliorates rodent experimental autoimmune encephalomyelitis (EAE), a model of human MS.||4|